BMS's Opdivo more than doubles 1-year survival in lung cancer
This article was originally published in Scrip
Executive Summary
Enthusiasm for Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) grew on 30 October when the company revealed Phase II data that showed one-year survival was more than double historical results in third-line treatment of squamous cell non-small cell lung cancer (NSCLC) patients.